黄连素新功能:可提高女性受孕率
科技日报 · 2016/01/26
临床中一直用来治疗痢疾和肠胃炎的黄连素,竟在改善女性生殖功能方面也会“有一手”。由国家中医临床研究基地妇科病建设首席科学家、黑龙江中医药大学附属第一医院妇产科主任吴效科教授领衔完成的一项国内外样本量最大的多囊卵巢综合征科研课题,首次发现黄连素具有促进排卵、提高受孕率和活产率的生殖疗效。


临床中一直用来治疗痢疾和肠胃炎的黄连素,竟在改善女性生殖功能方面也会“有一手”。记者近日从黑龙江中医药大学获悉,由国家中医临床研究基地妇科病建设首席科学家、黑龙江中医药大学附属第一医院妇产科主任吴效科教授领衔完成的一项国内外样本量最大的多囊卵巢综合征(PCOS)科研课题,首次发现黄连素具有促进排卵、提高受孕率和活产率的生殖疗效。相关临床研究成果刊发于最新一期国际著名期刊《柳叶刀》上。

作为一种重要的生物碱,黄连素可从中草药黄连、黄柏、三颗针等植物中提取。常用的盐酸黄连素又叫盐酸小檗碱,能对抗病原微生物,且对多种细菌如痢疾杆菌、结核杆菌等均有显著抑制效果,临床常用来治疗细菌性胃肠炎、痢疾等消化道疾病。现代药理学研究证实,黄连素还具有抗心力衰竭、降低胆固醇等诸多功效。

那么,黄连素能不能在解决不孕症难题上也会书写“老兵新传”呢?据介绍,当前不孕症发生比率逐年上升,占育龄期女性5%—10%,而不孕症中以多囊卵巢综合征(PCOS)最为多见。这其中,月经异常、糖脂代谢异常和胰岛素抵抗为多囊卵巢综合征的典型特点。吴效科课题组通过研究证实,黄连素之所以对治疗多囊卵巢综合征(PCOS)行之有效,是通过解除卵巢胰岛素抵抗促进排卵、降低雄激素合成而最终实现的。

与此同时,吴效科教授课题组还开展了黄连素多中心、随机、双盲、安慰及对照试验。首次发现黄连素活产率的疗效类似西医一线药物克罗米芬,黄连素口服6个月后PCOS不孕患者的活产率约为22%。而且黄连素很少有恶心、便秘等不良反应。

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Letrozole, berberine, or a combination for infertility in Chinese women with polycystic ovary syndrome: a multicentre, randomised, double-blind, placebo-controlled trial

    Background Letrozole is superior to clomiphene in infertile women with polycystic ovary syndrome and leads to higher ovulation and live birth rates. Berberine, a major active component of Chinese herbal medicine Rhizoma coptidis and found in Cortex Phellodendri and Cortex Berberidis in the rest of the world, has similar but even more profound metabolic effects than metformin. Our hypothesis was that a combination of letrozole and berberine would result in a higher live birth rate than letrozole or berberine alone in infertile women with polycystic ovary syndrome. Methods In this multicentre, randomised, double-blind, placebo-controlled trial in 19 participating centres in mainland China, we compared the effect of three interventions for up to six menstrual cycles: letrozole plus berberine placebo (letrozole group), berberine plus letrozole placebo (berberine group), or the combination of letrozole and berberine (combination group). The randomisation (1:1:1) was done through a web-based computer program operated by an independent data center in the China Academy of Chinese Medical Sciences. Participants, investigators, doctors, laboratory technicians, and data analysers were masked to the assignments. Eligible women (age 20–40 years) had polycystic ovary syndrome, as defined by the Rotterdam criteria, had at least one open Fallopian tube and normal uterine cavity, and had at least 1 year of infertility. Berberine or berberine placebo were administrated orally at a daily dose of 1·5 g for 6 months. Patients received an initial dose of 2·5 mg of letrozole or placebo on days 3–7 of the first three treatment cycles. This dose was increased to 5 mg letrozole or placebo on days 3–7 of the last three treatment cycles if not pregnant. Couples were instructed to have regular intercourse two to three times a week until becoming pregnant. The primary outcome was live birth rate after intervention for up to six menstrual cycles. We used either a χ2 test or Fisher's exact test a two-sided significance level of 0·05 to test differences between groups. Data were analysed according to the intention-to-treat principle. This study was approved by an Ethics Committee (2009LL-001) at First Affiliated Hospital in Heilongjiang University of Chinese Medicine. This trial is registered at Chinese Clinical Trials Registration, identifier ChiCTR-TRC-09000376, and at ClinicalTrials.gov, number NCT01116167. All participants provided written informed consent. Findings We enrolled 644 participants. The live birth rates were comparable between the letrozole group (78 [36%] of 215 births) and the combination group (74 [34%] of 215 birth) after treatment (odds ratio [OR] 0·92, 95% CI 0·62–1·37; p=0·687), whereas live birth rates in the berberine group (44 [22%] of 214 births) were lower than in the letrozole group (OR 2·02, 95% CI 1·32–3·10; p=0·001) and the combination group (OR 1·86, 95% CI 1·21–2·86; p=0·004). Conception, pregnancy, and ovulation rates were similar in the letrozole (46%, 39%, and 59%, respectively) and combination groups (49%, 38%, and 61%, respectively), and these were higher than in the berberine group. There was one twin birth in the letrozole group and three twin births in the combination group, but none in the berberine group (29%, 22%, and 6%, respecitively). Berberine was associated with constipation and nausea whereas letrozole was associated with fatigue and hot flashes. Interpretation For ovulation and live births, the combination of letrozole and berberine did not improve outcomes compared with letrozole alone, but letrozole and the combination of letrozole and berberine improved fertility in women with polycystic ovary syndrome compared with berberine alone. Some limitations include the early study termination because of the expiration of the study drug berberine or placebo, not all participants had pelvic sonograms to assess for polycystic ovaries, and some participants had regular cycles. The major strength of this study is that it was a large multicentre, double-blind trial with close monitoring of adverse events and serious adverse events and tracking of live birth in line with our recent Harbin consensus. Funding National Public Welfare Projects for Chinese Medicine (200807021) of China, the National Key Discipline of Chinese Medicine in Gynecology during the year of 2009–14, the Heilongjiang Province Foundation for Outstanding Youths (JC200804), the Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine Theory—‘TianGui Shi Xu’ (2011TD006), and the National Clinical Trial Base in Chinese Medicine during the year of 2009–14 in First Affiliated Hospital, Heilongjiang University of Chinese Medicine.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test